MannKind Will Seek Approval for Insulin

0

MannKind Corp. said it is close to asking for the Food and Drug Administration’s approval on its inhaled insulin product.


In presentations to investors Wednesday and Thursday, the company’s management said its new inhaled insulin product, Technosphere insulin, will likely become the first “super-rapid-acting insulin” product for the treatment of diabetes.


The drug has not shown signs of side effects that have caused wariness about other inhaled insulin products.


This announcement comes a month after Pfizer Inc. said it found that patients using its inhaled insulin drug, Exubera, had developed lung cancer.


Shares in MannKind of Valencia closed up 3 percent to $2.80 Thursday and continued to gain 6.4 percent in after-hours trading to $2.97.

No posts to display